Sort   by:  
 Page size 
ProteomicsCalreticulin mutated hematopoietic cells are vulnerable to ATR-CHK1 pathway inhibition
Disease frameshift mutations of calreticulin (CALR) are the second most prevalent driver mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF). To identify potential targeted therapies for CALR mutated myeloproliferative neoplasms, we aimed to search for small molecule drugs th...
ORGANISM(S): Mus musculus (Mouse) 
2021-09-07 | PXD026803 | Pride
Mouse Mpn Calreticulin mutant Myeloproliferative neoplasms Atr-chk1 pathway 
UnknownAntibody targeting of mutant calreticulin in myeloproliferative neoplasms.
Not available
S-EPMC10902560 | biostudies-literature
TranscriptomicsRNA seq of natural killer (NK) cells of MPN patients with mutations in calreticulin (CALR) and healthy controls
To assess the transcriptional differences between natural killer (NK) cells from patients with myeloproliferative neoplasms (MPN) carrying a mutation in calreticulin (CALR) and healthy donors (HD), bulk RNA sequencing was performed. Peripheral blood mononuclear cells (PBMC) were isolated from the bl...
ORGANISM(S): Homo sapiens 
2026-09-30 | E-MTAB-16774 | biostudies-arrayexpress
ProteomicsMutant calreticulin binders analysis
Mutant, truncated and wild-type human calreticul was co-purified with binding proteins
ORGANISM(S): Homo sapiens (Human) Mus musculus (Mouse) 
2018-10-11 | PXD008476 | Pride
Calreticulin mutation immunoprecipitation 
UnknownMutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism.
Not available
S-EPMC4877170 | biostudies-literature
UnknownMutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Not available
S-EPMC4851866 | biostudies-literature
UnknownDefective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
Not available
S-EPMC6952826 | biostudies-literature
GenomicsFirst-in-Class CAR T Cell Therapy Selectively Eliminates Mutant Calreticulin-Driven Malignancies in a Fibrotic Niche
First-in-Class CAR T Cell Therapy Selectively Eliminates Mutant Calreticulin-Driven Malignancies in a Fibrotic Niche
PRJNA1255181 | ENA
UnknownLysosomal degradation targets mutant calreticulin and the thrombopoietin receptor in myeloproliferative neoplasms.
Not available
S-EPMC11255115 | biostudies-literature
UnknownHematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
Not available
S-EPMC8118640 | biostudies-literature
Sort   by:  
 Page size